Cytokines include interferons, interleukins, growth factors and other molecules involved in signalling between cells. They play important stimulatory or inhibitory roles in a wide range of normal and pathologic processes such as growth regulation, inflammation, repair, viral and malignant diseases. The long-term objective of this research proposal is to define the role in tumor formation, spread or treatment of a new human cytokine, which we call hIRH, in selected gastrointestinal tissues and malignancies. Subtractive hybridization techniques to compare differences in gene expression at the cDNA level have been used to isolate potentially important genes in malignancy, such as the metastasis suppressor gene nm23. For a more rapid determination of differential gene expression at the cDNA level the technique of differential display has detected new genes, or suggested new roles for known genes in selected malignancies, e.g. maspin and integrins in breast cancer, PTI-1 in prostate cancer. We have isolated, by differential display, a range of new and known genes which we have determined to be differentially expressed in several gastrointestinal malignancies. This proposal focuses on one such gene, hIRH, isolated from differential displays of hepatocellular carcinoma and adjacent non-neoplastic liver, and continues studies to define its potential role in selected gastrointestinal malignancies.
The specific aims are to define 1) the genetic structure, and 2) the possible functional role in hepatocellular carcinoma and other tissues, of hIRH which we have determined to be almost uniformly lost from hepatocellular carcinomas, in comparison with the adjacent non-neoplastic livers. Similar cytokines are important either directly, or indirectly via the induction of an inflammatory response, in the inhibition of tumor growth. We plan to assess the activity of hIRH on leukocyte chemotaxis and in growth inhibition, both highly significant processes in tumor biology.

National Institute of Health (NIH)
National Cancer Institute (NCI)
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
Application #
Study Section
General Medicine A Subcommittee 2 (GMA)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Massachusetts Medical School Worcester
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Katsuta, T; Lim, C; Shimoda, K et al. (2000) Interleukin-8 and SDF1-alpha mRNA expression in colonic biopsies from patients with inflammatory bowel disease. Am J Gastroenterol 95:3157-64
Mitra, P; Shibuta, K; Mathai, J et al. (1999) CXCR4 mRNA expression in colon, esophageal and gastric cancers and hepatitis C infected liver. Int J Oncol 14:917-25
Begum, N A; Shibuta, K; Mori, M et al. (1999) Reduced expression of the CXCR4 receptor mRNA in hepatocellular carcinoma and lack of inducibility of its ligand alpha-chemokine hIRH/SDF1alpha/PBSF in vitro. Int J Oncol 14:927-34
Mathai, J; Shimoda, K; Banner, B F et al. (1999) IFN-alpha receptor mRNA expression in a United States sample with predominantly genotype 1a/I chronic hepatitis C liver biopsies correlates with response to IFN therapy. J Interferon Cytokine Res 19:1011-8
Shimoda, K; Mori, M; Shibuta, K et al. (1999) Vascular endothelial growth factor/vascular permeability factor mRNA expression in patients with chronic hepatitis C and hepatocellular carcinoma. Int J Oncol 14:353-9
Yamagata, M; Mori, M; Begum, N A et al. (1998) Glyceraldehyde-3-phosphate dehydrogenase mRNA expression in hepatocellular carcinoma. Int J Oncol 12:677-83
Bonkovsky, H L; Barnard, G F (1998) Diagnosis of porphyric syndromes: a practical approach in the era of molecular biology. Semin Liver Dis 18:57-65
Shimoda, K; Begum, N A; Shibuta, K et al. (1998) Interleukin-8 and hIRH (SDF1-alpha/PBSF) mRNA expression and histological activity index in patients with chronic hepatitis C. Hepatology 28:108-15
Shibuta, K; Begum, N A; Mori, M et al. (1997) Reduced expression of the CXC chemokine hIRH/SDF-1alpha mRNA in hepatoma and digestive tract cancer. Int J Cancer 73:656-62